Literature DB >> 31815554

Physical stability of dry powder inhaler formulations.

Nivedita Shetty1, David Cipolla2, Heejun Park1, Qi Tony Zhou1.   

Abstract

Introduction: Dry powder inhalers (DPIs) are popular for pulmonary drug delivery. Various techniques have been employed to produce inhalation drug particles and improve the delivery efficiency of DPI formulations. Physical stability of these DPI formulations is critical to ensure the delivery of a reproducible dose to the airways over the shelf-life.Areas covered: This review focuses on the impact of solid-state stability on aerosolization performance of DPI drug particles manufactured by powder production approaches and particle-engineering techniques. It also highlights the different analytical tools that can be used to characterize the physical instability originating from production and storage.Expert opinion: A majority of the DPI literature focuses on the effects of physico-chemical properties such as size, morphology, and density on aerosolization. While little has been reported on the physical stability, particularly the stability of engineered drug particles for use in DPIs. Literature data have shown that different particle-engineering methods and storage conditions may cause physical instability of dry powders for inhalation and can significantly change the aerosol performance. A systematic examination of physical instability mechanisms in DPI formulations is necessary during formulation development in order to select the optimum formulation with satisfactory stability. In addition, the use of appropriate characterization tools is critical to detect and understand physical instability during the development of DPI formulations.

Entities:  

Keywords:  Dry powder inhaler; aerosol performance; particle engineering; physical stability; powder characterization

Mesh:

Substances:

Year:  2019        PMID: 31815554      PMCID: PMC6981243          DOI: 10.1080/17425247.2020.1702643

Source DB:  PubMed          Journal:  Expert Opin Drug Deliv        ISSN: 1742-5247            Impact factor:   6.648


  160 in total

1.  The cohesive-adhesive balances in dry powder inhaler formulations I: Direct quantification by atomic force microscopy.

Authors:  Philippe Begat; David A V Morton; John N Staniforth; Robert Price
Journal:  Pharm Res       Date:  2004-09       Impact factor: 4.200

Review 2.  Dry powder inhaler formulation.

Authors:  Martin J Telko; Anthony J Hickey
Journal:  Respir Care       Date:  2005-09       Impact factor: 2.258

3.  Polymorph screening of an active material.

Authors:  P Láng; V Kiss; R Ambrus; G Farkas; P Szabó-Révész; Z Aigner; E Várkonyi
Journal:  J Pharm Biomed Anal       Date:  2013-06-14       Impact factor: 3.935

4.  The quantitative analysis of crystallinity using FT-Raman spectroscopy.

Authors:  L S Taylor; G Zografi
Journal:  Pharm Res       Date:  1998-05       Impact factor: 4.200

Review 5.  Non-invasive delivery strategies for biologics.

Authors:  Aaron C Anselmo; Yatin Gokarn; Samir Mitragotri
Journal:  Nat Rev Drug Discov       Date:  2018-11-30       Impact factor: 84.694

Review 6.  Dry powder inhalers: advantages and limitations.

Authors:  G K Crompton
Journal:  J Aerosol Med       Date:  1991

7.  Spray dried powders and powder blends of recombinant human deoxyribonuclease (rhDNase) for aerosol delivery.

Authors:  H K Chan; A Clark; I Gonda; M Mumenthaler; C Hsu
Journal:  Pharm Res       Date:  1997-04       Impact factor: 4.200

8.  The influence of surface active l-leucine and 1,2-dipalmitoyl-sn-glycero-3-phosphatidylcholine (DPPC) in the improvement of aerosolization of pyrazinamide and moxifloxacin co-spray dried powders.

Authors:  Basanth Babu Eedara; Bhamini Rangnekar; Colin Doyle; Alex Cavallaro; Shyamal C Das
Journal:  Int J Pharm       Date:  2018-03-07       Impact factor: 5.875

9.  Co-spray-dried mannitol-ciprofloxacin dry powder inhaler formulation for cystic fibrosis and chronic obstructive pulmonary disease.

Authors:  Handoko Adi; Paul M Young; Hak-Kim Chan; Helen Agus; Daniela Traini
Journal:  Eur J Pharm Sci       Date:  2010-04-03       Impact factor: 4.384

10.  Effect of humidity on aerosolization of micronized drugs.

Authors:  Paul M Young; Robert Price; Michael J Tobyn; Mark Buttrum; Fiona Dey
Journal:  Drug Dev Ind Pharm       Date:  2003-10       Impact factor: 3.225

View more
  9 in total

Review 1.  Novel Approaches for the Treatment of Pulmonary Tuberculosis.

Authors:  Zhi Ming Tan; Gui Ping Lai; Manisha Pandey; Teerapol Srichana; Mallikarjuna Rao Pichika; Bapi Gorain; Subrat Kumar Bhattamishra; Hira Choudhury
Journal:  Pharmaceutics       Date:  2020-12-10       Impact factor: 6.321

2.  Spray-freeze-dried inhalable composite microparticles containing nanoparticles of combinational drugs for potential treatment of lung infections caused by Pseudomonas aeruginosa.

Authors:  Shihui Yu; Xiaohui Pu; Maizbha Uddin Ahmed; Heidi H Yu; Tarun Tejasvi Mutukuri; Jian Li; Qi Tony Zhou
Journal:  Int J Pharm       Date:  2021-10-06       Impact factor: 5.875

3.  Spray-Dried and Spray-Freeze-Dried Powder Formulations of an Anti-Interleukin-4Rα Antibody for Pulmonary Delivery.

Authors:  Harry W Pan; Han Cong Seow; Jason C K Lo; Jinlin Guo; Lingqiao Zhu; Susan W S Leung; Chenghai Zhang; Jenny K W Lam
Journal:  Pharm Res       Date:  2022-07-25       Impact factor: 4.580

4.  Micro-fluidic Spray Freeze Dried Ciprofloxacin Hydrochloride-Embedded Dry Powder for Inhalation.

Authors:  Yingjie Chen; Shen Yan; Shengyu Zhang; Quanyi Yin; Xiao Dong Chen; Winston Duo Wu
Journal:  AAPS PharmSciTech       Date:  2022-08-02       Impact factor: 4.026

5.  Pulmonary Targeting of Levofloxacin Using Microsphere-Based Dry Powder Inhalation.

Authors:  Turki Al Hagbani; Bhavya Vishwa; Amr S Abu Lila; Hadil Faris Alotaibi; El-Sayed Khafagy; Afrasim Moin; Devegowda V Gowda
Journal:  Pharmaceuticals (Basel)       Date:  2022-04-30

6.  In vitro evaluation of drug delivery behavior for inhalable amorphous nanoparticle formulations in a human lung epithelial cell model.

Authors:  Jianting Chen; Maizbha U Ahmed; Chune Zhu; Shihui Yu; Weisan Pan; Tony Velkov; Jian Li; Qi Tony Zhou
Journal:  Int J Pharm       Date:  2021-01-21       Impact factor: 5.875

Review 7.  Inhaled RNA Therapeutics for Obstructive Airway Diseases: Recent Advances and Future Prospects.

Authors:  You Xu; Aneesh Thakur; Yibang Zhang; Camilla Foged
Journal:  Pharmaceutics       Date:  2021-01-28       Impact factor: 6.321

Review 8.  Inhaled antibodies: Quality and performance considerations.

Authors:  Anthony James Hickey; Ian Edward Stewart
Journal:  Hum Vaccin Immunother       Date:  2021-06-30       Impact factor: 4.526

9.  Cylindrical Microparticles Composed of Mesoporous Silica Nanoparticles for the Targeted Delivery of a Small Molecule and a Macromolecular Drug to the Lungs: Exemplified with Curcumin and siRNA.

Authors:  Thorben Fischer; Inga Winter; Robert Drumm; Marc Schneider
Journal:  Pharmaceutics       Date:  2021-06-07       Impact factor: 6.321

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.